Reshape Biotech

Reshape Biotech is building the next generation of lab automation robots. Our customers are biotech companies tackling the world's biggest problems - be it alternative protein development or sustainable agriculture. Reshape Biotech is the scaling factor for these companies, as we let researchers collaborate globally on experiments and increase their throughput >500x. The team is highly multi-disciplinary, employing everything from PhD's in biology to hardware and software engineers. We work closely together, and you will be exposed to a truly vertical team. We're a fast growing startup with an incredibly ambitious team, dead-set on reinventing a 100 year old industry and becoming the standard infrastructure that the world of biotech relies on. Our customers already include global leaders in food, agriculture and biologicals. We're backed by top tier investors from Y Combinator, CEOs from the industry and some of the biggest names you can find. At Reshape Biotech, you have the potential to influence how biotech research is done in the next 100 years.

Research Copenhagen, Denmark ~65 employees Private · Series A

Work at Reshape Biotech in HR or recruiting? Claim this page

Employees
65
0% in the 3 months to Sep 2026
Revenue / employee
$123K
Revenue ~$8M
Total funding
$29.2M
Last round Series A, Apr 2024
12-month attrition
150%
H1B sponsor
NA

Headcount trend

Reshape Biotech went from 0 employees in Oct 2024 to 0 in Sep 2026.

Funding rounds

Total funding$29.2M
Funding rounds4
Investors6
DateRoundMoney raisedNo.Investors
Apr 2024Series A$20M5
Feb 2023Seed$8.1M3
May 2021Seed$983K2
Dec 2020Funding$130K––

Reshape Biotech FAQ

How many employees does Reshape Biotech have?

Reshape Biotech has about 65 employees, unchanged over the 3 months to Sep 2026.

What is Reshape Biotech's revenue per employee?

Reshape Biotech makes about $123K in revenue per employee, based on $8M annual revenue and 65 employees.

How much funding has Reshape Biotech raised?

Reshape Biotech has raised $29.21M in total funding; its latest round was Series A in Apr 2024.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.